What the FDA Initial Importer Is Actually Responsible For

Importing a device is not merely a customs transaction. An FDA “initial importer” is generally the first U.S. importer that furthers the marketing of a finished device from a foreign manufacturer toward the ultimate consumer or user without repackaging or relabeling it. The role is distinct from the customs Importer of Record and the foreign manufacturer’s U.S. Agent. The initial importer must maintain a staffed U.S. establishment, register with FDA, renew annually, pay the applicable establishment fee, and identify the foreign manufacturers whose devices it imports. Initial importers register but ordinarily do not separately list the devices.

Responsibilities After Entry

The more significant responsibilities begin after entry. The importer needs a functioning process for receiving and escalating complaints, forwarding both MDR and non-MDR complaints to the manufacturer, evaluating adverse-event information, and maintaining MDR event files. Deaths and serious injuries potentially associated with an imported device must generally be reported to FDA and the manufacturer within the applicable 30-day period. Certain reportable malfunctions must be reported to the manufacturer even when no injury has occurred.

Initial importers can also have direct responsibilities for corrections, removals, and recalls. Under 21 CFR Part 806, a manufacturer or importer that initiates action to reduce a risk to health or remedy a violation that may present a risk to health may need to report it promptly to FDA. Records must also be maintained for corrections and removals that are not reportable. Distribution records should therefore identify affected devices, lot or serial numbers, shipment dates, quantities, and consignees.

Preparing for the Unexpected

A draft recall plan should exist before the first commercial shipment. It should identify decision-makers and alternates; FDA and manufacturer contacts; safety-escalation routes; access to technical and health-hazard information; inventory holds; consignee or patient tracing; recall depth; notification templates; product return, correction, destruction, and reconciliation; effectiveness checks; and FDA reporting. Critically, it should include an “orphaned product” scenario in which the foreign manufacturer becomes insolvent, dissolves, loses key personnel, refuses cooperation, or can no longer supply records or technical support.

The foreign manufacturer’s disappearance does not erase the initial importer’s obligations for devices already placed into U.S. commerce. MDR records may require retention for two years from the event or for the device’s expected life, whichever is longer, even after distribution stops. The importer does not automatically become the legal manufacturer, but may remain the only functioning U.S. organization able to receive complaints, contact consignees, preserve records, cooperate with FDA, and support an urgent field action. Contracts should therefore secure continuing access to complaint data, device history, technical expertise, insurance, recall funding, and transferable records before importation begins.

The MDD Options Hybrid model makes the initial-importer role operational rather than nominal. MDD Options can combine FDA registration, controlled importation, complaint and MDR routing, serialized distribution records, and recall-ready fulfillment within one accountable U.S. platform, while establishing continuity measures for circumstances in which the foreign manufacturer becomes unavailable.